|Docket No.||Op. Below||Argument||Opinion||Vote||Author||Term|
|10-844||Fed. Cir.||Dec 5, 2011||Apr 17, 2012||9-0||Kagan||OT 2011|
Holding: A generic drug manufacturer may employ the counterclaim provision of the Hatch-Waxman Act to force correction of a use code that inaccurately describes the brand’s patent as covering a particular method of using a drug.
Judgment: Reversed and remanded, 9-0, in an opinion by Justice Kagan on April 17, 2012. Justice Sotomayor filed a concurring opinion.
Merits Briefs for Petitioners
Amicus Briefs Supporting Petitioners
Merits Briefs for the Respondents
Amicus Briefs Supporting the Respondents